Radioimmunotherapy delivers radiation to a target cell using radiolabeled monoclonal antibodies and has been evaluated for the treatment of various cancers. As opposed to traditional external beam radiation therapy that is used for the treatment of localized cancers, radioimmunotherapy is administered by intravenous injection and can be used to treat disseminated cancers. The targeted delivery of the radiation to cancer cells minimizes damage to normal tissues and thereby reduces toxicities. In general, monoclonal antibodies used in radioimmunotherapy target tumor-associated antigens preferentially expressed on the surface of cancer cells. Y-daclizumab acts might be by depletion of Tregs and Th2 in the tumor microenvironment and disruption of the supporting stroma in Hodgkin lymphoma. However, the major mechanism of action is likely a result of the "crossfire" effect mediated by 90 Y (1), which emits β-particles that can travel up to 11 mm in the tissues and kill other nontargeted cells in the vicinity, including Reed-Sternberg cells that do not express CD25. This finding is supported by the observation that the response rates were comparable between patients whose tumors expressed CD25 on Reed-Sternberg cells and those that did not. Moreover, apoptosis and DNA double-strand breaks were observed in the tumor cells early after administration of 90 Y-daclizumab, although the small sample size precluded definitive conclusions (2) .
Although the crossfire effect is likely important for the efficacy of this agent, it might also be responsible for its toxicity. In particular, neutropenia and thrombocytopenia are likely caused by the crossfire effect on hematopoietic precursors in the bone marrow. The myelodysplastic syndrome (MDS) observed in 6 of 46 (13%) subjects treated on this trial may also be caused by the crossfire effect on hematopoietic precursors. However, this is less likely, as development of MDS was not observed in the second cohort of 16 patients that were screened for preexisting chromosomal aberrations before study entry and were excluded if they did. This notion is also supported by the observation of cytogenetic aberrations in chromosomes 5 and 7 before therapy with 90 Y-daclizumab in one patient that developed MDS on the study (2). Moreover, the incidence of MDS was found to be low in patients treated with other radioimmunotherapy agents (8, 9 In-daclizumab was similar to sites of disease identified by standard imaging studies and was not affected by the presence or absence of CD25 expression on Reed-Sternberg cells. This finding further supports the rationale for targeting CD25 on the rosetting T cells in the tumor microenvironment in Hodgkin lymphoma. Whether this approach of targeting the stromal cells in the tumor niche to induce tumor cell death by crossfire will be applicable to other cancers, especially solid tumors, remains to be determined. It is possible that Hodgkin lymphoma may be uniquely suited for this approach because the malignant Reed-Sternberg cells account for only about 1% of the tumor, and nonmalignant reactive cells are the dominant population in the tumor microenvironment (7). Moreover, Hodgkin lymphoma is highly sensitive to radiation compared with solid tumors. Nonetheless, most cancers have a stromal cell component that supports the growth of the tumor either directly or indirectly by promoting immune escape, as in the case of Tregs. Therefore, 90 Y-daclizumab may be useful in other cancers to lower the number of Tregs and promote antitumor immune responses. Indeed, a significant reduction in circulating Tregs was observed in this study (7) . Recently, treatment with an immune checkpoint inhibitor, nivolumab, a monoclonal antibody against programmed death-1 (PD-1), was shown to induce an impressive overall response rate of 87% in subjects with relapsed or refractory Hodgkin lymphoma, suggesting that this lymphoma may be particularly immune responsive (10) . Therefore, 90 Y-daclizumab could act by decreasing Tregs and promoting antitumor immunity in Hodgkin lymphoma. Future trials with combinations of 90 Y-daclizumab and immune checkpoint inhibitors, such as anti-PD-1 antibody, or immune activating agents, such as vaccines, could have complementary and possibly synergistic effects. Furthermore, targeting other supporting stromal cells in the tumor microenvironment in Hodgkin lymphoma-including macrophages, B cells, neutrophils, fibroblasts, and so forth-could also be beneficial (7) . Indeed, depletion of infiltrating benign B cells with rituximab, an anti-CD20 monoclonal antibody, has been shown to induce clinical responses in Hodgkin lymphoma (11) (12) (13) .
Although all subjects had CD25 + rosetting T cells around Reed-Sternberg cells in their tumors, half of them did not achieve an objective response. Moreover, the median duration of response of 151 d was short (2) . This result may be because of the presence of radiation-resistant tumor cells or, alternatively, because of heterogeneity in the tumor-stroma architecture at different disease sites, resulting in tumor cells being out of range for the crossfire effect. Investigating these resistance mechanisms is necessary to improve the efficacy of this therapy and to develop novel combination strategies. It is also important to determine the relative contribution of the crossfire effect and Treg depletion in the efficacy of this agent. If the former is the dominant mechanism, then strategies to enhance the crossfire effect to increase efficacy while decreasing toxicity should be explored. If the latter is more important, evaluation of agents, such as anti-CTLA-4 monoclonal antibody, which can impact both effector and regulatory T cells to drive effector T-cell responses while possibly also depleting Tregs, may be considered for combination strategies (14) (15) (16) (17) . In addition, combination approaches with other immune checkpoint inhibitors and immune activating agents, including OX-40 antibody (18) (19) (20) , and targeting of other stromal cells, such as macrophages and B cells (11) that support tumor growth, may be investigated.
In summary, the report by Janik et al. (2) provides an important proof-of-concept that durable clinical responses are achievable by targeting the tumor niche and inducing cancer cell death by crossfire using β-particleemitting radioimmunotherapy. The results of Janik et al. suggest that 90 Y-daclizumab is a promising agent for the treatment of Hodgkin lymphoma. However, better understanding of the mechanisms of action and toxicities is needed to improve its efficacy and safety. The Treg-depleting property of this agent could potentially be used to develop novel immunotherapy strategies for other malignancies.
